Adverse drug reactions
Andexanet shows promise in patients taking new anticoagulants
Results from an ongoing trial of 228 patients with acute major bleeding show that patients taking andexanet experienced a reduction in anti-FXa activity.
Source: Biophoto Associates / Science Photo Library
Factor Xa (FXa) inhibitor reversal agent andexanet rapidly restores haemostasis with an “acceptable” rate of adverse events, in patients taking an FXa inhibitor, a class of anticoagulants including rivaroxaban and apixaban, researchers have found.
Speaking at the American College of Cardiology Annual Scientific Session, held in Orlando, Florida, in March 2018, the researchers presented results from their ongoing uncontrolled trial of andexanet, involving 228 patients who presented with acute major bleeding after taking an FXa inhibitor.
The team found that patients receiving an andexanet infusion experienced a median reduction in anti-FXa activity of 92%. At 12 hours, 83% of patients had achieved good or excellent haemostasis. After 30 days, 11% of patients had experienced a thrombotic event and 12% had died.
There are currently no approved reversal agents in the event of potentially fatal, uncontrolled bleeding while taking an FXa inhibitor, therefore some doctors and patients may choose to use other anticoagulants because they have reversal agents.
“Having a safe and effective reversal agent available will benefit patients with acute bleeding,” said lead researcher Stuart Connolly.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204839
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now